The Citizens Commission on Human Rights (CCHR) has issued a call for consumers to scrutinize psychotropic prescription drug labeling for warnings about suicide, aggression, and homicidal ideation, and to demand that prescribing physicians explain these risks, even when they are labeled as rare. This follows news reports of violent crimes committed by individuals reportedly taking or withdrawing from antidepressants, stimulants, or other psychiatric drugs known to have such side effects.
CCHR's decades-long campaign has highlighted cases where psychiatric drugs have been linked to agitation, aggression, and suicidal or homicidal thoughts. Regulatory bodies in the U.S. and abroad have responded by requiring warnings on various medications. Jan Eastgate, president of CCHR International, emphasized that a rare warning in a package insert is insufficient: "Listing a side effect as 'rare' does not establish that the patient was told about it, understood it or agreed to take that risk. Meaningful informed consent requires meaningful disclosure and prescriber accountability."
The legal and professional implications are being debated. Psychiatric Times recently discussed whether psychiatrists are responsible for patients' criminal behavior, noting that litigation places mental health providers under scrutiny. The doctrine of involuntary intoxication may apply in some cases, but its applicability depends on whether the drug was taken as prescribed and whether the patient knew of potential effects.
CCHR points to a significant increase in regulatory warnings: since 2004, there have been 57 warnings about violence, aggression, or hostility, a 1,040% increase from just five in 2004. Thirteen specifically mention homicidal ideation. For example, extended-release venlafaxine labeling added homicidal ideation in 2005, and bupropion received a boxed warning in 2009 for neuropsychiatric events, including hostility and suicidal ideation. In 2023, the FDA required class-wide warnings for CNS stimulants about anxiety, psychosis, and aggressive behavior. Esketamine nasal spray labeling instructs patients to seek help for sudden mood changes, including aggression or violence. Aripiprazole lists homicidal ideation among rare adverse reactions.
Eastgate stressed that printing a warning does not ensure patients see or understand it: "A judge allowing a jury to hear evidence about prescription drugs is not the same as a physician warning a patient before the first dose." This issue has entered public policy, with a 2026 Tennessee law requiring toxicology testing after violent incidents involving psychiatric drugs. CCHR urges similar laws nationwide.
CCHR maintains that the central issue is informed consent. Patients should read warnings and ask questions before starting treatment, and prescribers must explain potential violent and suicidal side effects, even rare ones. "A label alone does not ensure informed consent," Eastgate said. While not all patients will experience these reactions, they should be able to recognize warning signs and seek medical advice. Patients should not abruptly stop taking psychiatric drugs; any changes should be medically supervised.
CCHR, established in 1969 by the Church of Scientology and Dr. Thomas Szasz, advocates for transparent disclosure of risks and prescriber accountability as fundamental to informed consent.
